Active ingredientDacomitinibCat. No. P-D005-001CAS 1110813-31-4Family · Pharmaceutical analytical standards
Dacomitinib
A second-generation irreversible EGFR tyrosine kinase inhibitor, approved in the United States in 2018 as first-line treatment for metastatic non-small cell lung cancer with EGFR mutations. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It hooks onto a cysteine in the ATP site through a covalent bond and blocks not only EGFR but also its 'cousins' HER2 and HER4: hence it is called a pan-HER inhibitor.
Go to the active ingredient →Active ingredientDacomitinibCat. No. P-D005-001CAS 1110813-31-4
Isotopically labelledDacomitinib Impurity 2-d10Cat. No. P-D005-002
Isotopically labelledDacomitinib-d10Cat. No. P-D005-004
NitrosamineN-Nitroso DacomitinibCat. No. P-D005-005
ImpurityDacomitinib Impurity 1Cat. No. P-D005-006CAS 162012-67-1
ImpurityDacomitinib Impurity 2Cat. No. P-D005-007
ImpurityDacomitinib Impurity 3Cat. No. P-D005-008CAS 2190490-31-2
ImpurityDacomitinib Impurity 4Cat. No. P-D005-009CAS 2803478-54-6
ImpurityDacomitinib Impurity 5Cat. No. P-D005-010
ImpurityDacomitinib Z-isomerCat. No. P-D005-011
ImpurityDacomitinib Impurity 6Cat. No. P-D005-012CAS 179552-75-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.